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Introduction
Direct interactions of neighboring cells are conferred by several 
types of cellular junctions. These can functionally be grouped 
into occluding (i.e., tight junctions), anchoring (i.e., adherens 
junctions, desmosomes and hemidesmosomes) and communi-
cating junctions (i.e., gap junctions). Tight junctions (TJs) are 
characterized by dynamic and highly organized plasma mem-
brane-bound structures, which seal the paracellular space in 
order to allow the establishment and maintenance of a distinct 
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Zonula occludens proteins (Zo-1, Zo-2, Zo-3), which belong to 
the family of membrane-associated guanylate kinase (MAgUK) 
homologs, serve as molecular hubs for the assembly of multi-
protein networks at the cytoplasmic surface of intercellular 
contacts in epithelial and endothelial cells. These multi-pDZ 
proteins exert crucial functions in the structural organization 
of intercellular contacts and in transducing intracellular signals 
from the plasma membrane to the nucleus. The junctional 
MAgUK protein Zo-2 not only associates with the C-terminal 
pDZ-binding motif of various transmembrane junctional 
proteins but also transiently targets to the nucleus and interacts 
with a number of nuclear proteins, thereby modulating gene 
expression and cell proliferation. Recent evidence suggests 
that Zo-2 is also involved in stress response and cytoprotective 
mechanisms, which further highlights the multi-faceted nature 
of this pDZ domain-containing protein.
This review focuses on Zo-2 acting as a molecular scaffold 
at the cytoplasmic aspect of tight junctions and within the nu-
cleus and discusses additional aspects of its cellular activities. 
The multitude of proteins interacting with Zo-2 and the het-
erogeneity of proteins either influencing or being influenced 
by Zo-2 suggests an exceptional functional capacity of this 
protein far beyond merely serving as a structural component 
of cellular junctions.
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internal and external milieu in tissues and organs.1-3 The forma-
tion of such “ins” and “outs” is imperative for proper development 
and tissue function. For instance, the tight intercellular bonding 
between trophectoderm epithelial cells is necessary to create a 
suitable internal milieu for the developing mammalian embryo.4 
Or, the restrictive intercellular contacts between capillary endo-
thelial cells, forming the so called blood-brain barrier, enable 
a physiological functioning of the brain within a homeostatic 
environment and protect the vulnerable neural tissue from the 
uncontrolled entrance of substances emanating from the systemic 
circulation.5-8 Next to regulating the paracellular flux of solutes 
and ions, tight junctions also create a “fence” in the plane of the 
plasma membrane, contributing to the establishment of cellular 
polarity.9-12 Epithelial and endothelial tight junctions consist of 
several classes of transmembrane proteins locating to the apical 
aspect of the cell.13 The extracellular portions of the transmem-
brane proteins form a more or less tight seal between opposing 
cells, connecting the plasma membranes in a zipper-like fashion. 
Within the cell a highly organized cytoplasmic “plaque” consist-
ing of an array of cytosolic proteins assembles in close vicinity 
to these contact sites, providing mechanical linkage between 
the plasma membrane and the cytoskeleton. A large number of 
junctional proteins have been identified during the last decade 
(reviewed in 13-19) and soon it was realized that these complexes 
not only ensure the structural integrity of tight junctions,20-23 but 
also coordinate and transduce the signals impinging on and ema-
nating from the apical plasma membrane. Consequently, next to 
serving as physical barriers tight junctions also influence pivotal 
processes such as morphogenesis, gene expression, cytoskeletal 
dynamics and cell proliferation.14,18,24-26
PDZ-Containing Scaffolding Proteins:  
The Molecular Basis for Junctional Plaque 
Assembly
The most prominent subgroup of scaffolding proteins localiz-
ing to the cytoplasmic face of the adhesion site is represented 
by the MAGUK (membrane-associated guanylate kinase) pro-
teins,27-29 which can be classified into seven subfamilies based on 
their modular structure and sequence similarity.30 The modu-
lar nature of MAGUK proteins was early recognized and com-
prises one or more PDZ domains next to other protein-protein 
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for an ever growing list of junction-associated proteins. Next 
to the classical MAGUK domains, ZO proteins also contain 
a short binding region at the C-terminus (TEL), which repre-
sents an additional PDZ binding domain. Finally, a proline-rich 
region of varying length is present at the C-terminus of ZO-1 
and ZO-2 and between the second and third PDZ domain 
of ZO-3 and has been shown to be targeted by actin-binding 
proteins and other cytoskeletal proteins.38-40 In recent years, 
increasing interest has focused on the role of variable regions, 
numbered U (unique)1 to U6, which are localized between the 
core domains listed further above. The best studied variable 
region, termed HOOK domain (U5), is a basic hinge region 
between the SH3 and GUK domain which is involved in oligo-
merization and ligand binding of MAGUKs.41 The U6 motif is 
unique to ZO proteins and appears to be critical for junction 
assembly. For instance, expression of a mutant ZO-1, lacking 
the U6 region, induces ectopic junctional strands consisting 
of occludin and claudins but lacking most of the cytoplasmic 
plaque proteins.41
Other junctional MAGUK proteins identified so far include 
MAGI-1, -2 and -3 (membrane-associated guanylate kinase with 
inverted orientation of protein–protein interaction domains-1, 
-2 and -3),42-44 and the calcium/calmodulin-dependent ser-
ine protein kinase (CASK/LIN-2).45 In addition, the human 
homolog of the Drosophila discs large tumor suppressor hDlg/
SAP97 has been shown to localize to regions of cell-cell con-
tact.46,47 However the functional relevance of hDlg for TJ biol-
ogy remains poorly characterized.
Next to the MAGUK proteins, several other proteins localiz-
ing to the junctional plaque harbor one or more PDZ domains. 
These protein-protein interaction modules, which often bind to 
short amino acid motifs at the C-termini of target proteins, are 
named after the first three proteins in which these domains have 
been identified: PSD-95 (post synaptic density protein-95), 
Dlg (the Drosophila discs large protein) and ZO-1 (zonula 
occludens-1).48,49 At TJs, the large 13 PDZ domain-containing 
protein MUPP1 (multi PDZ domain protein-1)50 and ZO pro-
teins directly bind the cytoplasmic domains of the TJ-specific 
transmembrane proteins occludin and claudins.51-53 In a simi-
lar manner, the Ig-like junction adhesion molecule 1 (JAM1) 
anchors Par-3,54 and hence the Par6/aPKC (partitioning-defec-
tive protein-6/atypical protein kinase C) complex to the apical 
aspect of the plasma membrane.55 PALS1 binds to a cytoplasmic 
portion of the transmembrane proteins CRB (crumbs)-1 and 
CRB-3, thereby targeting the evolutionary conserved polarity 
complex CRB1/3-PALS1-PATJ to the junction.56 Further, the 
polarity protein Scribble, a large multi-domain protein involved 
in the maintenance of apical/basal polarity, migration and inva-
sion,57 was shown to associate with ZO-1 and has been dem-
onstrated to be important for TJ assembly.58 Finally, the Ras 
target AF-6/afadin59 directly interacts with ZO-1 and localizes 
to TJs. Taken together, PDZ domain-mediated protein-protein 
interactions aid in the temporal and spatial assembly of multi-
protein complexes at the cytoplasmic plaque and are pivotal for 
the functional and structural integrity of TJs (see Fig. 1).
binding domains including SH3 (Src homology 3), WW, L27 
(MAGUK LIN-2 + LIN-7), CaMK (calcium/calmodulin-
dependent protein kinase) domains and a GUK (guanylate 
kinase) domain,28 a region which lacks enzymatic activity due 
to a deletion in its ATP- and GMP-binding sites but appears 
to enable protein–protein binding.31 The most intensely stud-
ied junctional MAGUKs include the zonula occludens proteins 
(ZO-1, ZO-2 and ZO-3).32-35 Although originally described 
as TJ-specific proteins, ZO proteins also associate with other 
types of intercellular contacts, i.e., adherens and gap junctions 
(reviewed in 13, 14, 36, 37). Thus, ZO proteins appear to exert, 
at least in part, a basic and redundant role in establishing and/
or maintaining intercellular adhesion and communication. 
Generally, ZO proteins serve as a multivalent binding platform 
Figure 1. pDZ proteins as molecular base of tight junctional plaques. 
Two groups of proteins are involved in the establishment and mainte-
nance of TJs: (1) Transmembrane proteins which bridge the intercellular 
space and create a paracellular seal and (2) peripheral proteins, consti-
tuting the cytoplasmic “plaque” of tight junctions interacting directly or 
indirectly with the transmembrane junctional components. The forma-
tion of these complexes largely relies on pDZ-pDZ interactions. only 
cytosolic proteins harboring one or more pDZ domains are illustrated.
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Transmembrane proteins interacting with ZO-2 include the 
tetra-span proteins claudins and occludin.52,61 Claudin-1 to -8 
interact via their C-terminal region with the first PDZ domain,52 
while connexins (Cx), including Cx-36 and Cx-43, were found 
to associate with PDZ-1 or PDZ-2, respectively.62,63 Although 
the binding of occludin to a region at the SH3-hinge-GUK 
domain has only been demonstrated for ZO-1,64 a similar inter-
action can be presumed for ZO-2, although this remains to be 
demonstrated.
The proline-rich C-terminal domain of ZO-2 has been 
shown to interact mainly with cytoskeleton-associated proteins, 
including protein 4.1R and F-actin.38-40 Cingulin, a 140 kDa 
phosphoprotein and regulator of Rho-A signaling at TJs inter-
acts directly with ZO-2 and provides a direct link to the acto-
myosin cytoskeleton.65,66 Finally, data from a tandem proteomic 
approach suggests the direct or indirect interaction of ZO-2 
with 14–3-3 binding proteins, which are known to be involved 
Molecular Interactions of ZO-2 at the Junctional Site
Zonula occludens 2 (ZO-2) is a 160 kDa protein originally iden-
tified in a ZO-1 immunoprecipitate.32 Proteins interacting with 
ZO-2 at cell-cell contact sites essentially can be subdivided into 
structural and non-structural proteins. Figure 2 depicts a sche-
matic diagram of the ZO-2 interactome. Some of the protein-
protein interactions described for ZO-2 are redundant and have 
been shown for all ZO proteins. Such interactions include the 
binding of the first PDZ domain to the C-termini of claudins52 
or the homo- and hetero-dimerization of ZO-proteins via their 
second PDZ domain, which takes place by domain swapping of 
β1 and β2 strands.60 These redundancies are not surprising as the 
ZO proteins share a high degree of homology among each other. 
Nevertheless, ZO proteins also fulfill a multitude of ZO-specific 
functions.
Figure 2. The Zo-2 (TJp2) interactome. protein-protein interactions are symbolized by bold lines whereas outgoing dashed lines indicate that pertur-
bations of Zo-2 expression affect the expression of the indicated proteins. incoming dashed lines refer to proteins which impact upon the mRnA level 
of Zo-2. The graph was generated using the ipA software package (ingenuity Systems) and gene symbols according to the H.g.n.C. nomenclature are 
shown.
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influence of ZO-2 on cellular proliferation remain controversial. 
Exogenous downregulation of ZO-2 resulted in functional per-
turbations of TJs in epithelial cells without altering cell prolifera-
tion or apoptosis rates.84 Also, during mouse blastocyst formation 
repression of ZO-2 delayed the formation of the blastocoel cavity, 
without affecting cell proliferation.4 In contrast, deletion of ZO-2 
in mice is embryonic lethal shortly after implantation due to an 
arrest in early gastrulation. Interstingly, ZO-2 knockout embryos 
showed a decreased proliferation rate and an increase in apoptotic 
cells.85 Finally, the nuclear accumulation of a ZO-2 variant tagged 
with exogenous SV40 nuclear localization signals led to increased 
cell proliferation of epithelial and endothelial cells.86 In another 
study the overexpression of ZO-2 in epithelial cells resulted in 
binding to c-Myc triggering the downregulation of cyclin D1 and 
subsequent suppression of cell proliferation.87 Later, Lechuga S, et 
al. provided evidence that the inhibitory effect of ZO-2 on cyclin 
D1 transcription is blocked by ZASP (ZO-2 associated speckle 
protein) through binding to the third PDZ domain of ZO-2.88
Modulation of cell proliferation is also facilitated by bind-
ing of ZO-2 to the transcriptional activator YAP2 (Yes kinase-
associated protein 2), an effector of the Hippo signaling pathway 
which controls the regulation of proliferation and apoptosis dur-
ing mammalian organogenesis.89 Interaction with ZO-2, which 
can be abrogated by deletion of the 1st PDZ domain, enhances 
the nuclear localization and pro-apoptotic function of YAP.90 
Next to ZO-2, also ZO-1 has been identified as a binding partner 
of YAP-2, also known as TAZ (transcriptional coactivator with 
PDZ-binding motif).91 ZO-2 was also found to interact with the 
cytoskeletal protein LASP-1 (LIM-and-SH3-domain-protein-1), 
usually present in focal contacts, where it regulates cytoskeletal 
dynamics and cell migration. Phosphorylation of LASP-1 by PKA 
(protein kinase A) induces nuclear targeting of the LASP-1/ZO-2 
complex92 and nuclear accumulation of LASP-1 is thought to be 
relevant during cancer progression.
Several proteins have been found to interact with ZO-2 dur-
ing nuclear shuttling or within the nucleus itself. For example, 
the interaction of the armadillo-repeat protein ARVCF (armadillo 
repeat gene deleted in velocardiofacial syndrome) depends on an 
N-terminal PDZ domain of ZO-2,93 a region which is also targeted 
by the non-receptor tyrosine kinase JAK1. Also, the transcription 
factors Jun, Fos and C/EBP were shown to associate with ZO-2 
within the nucleus and at TJs in epithelial cells.94 Next to directly 
associating with and/or influencing transcription factors, ZO-2 
possibly impacts upon the transcription machinery via its associa-
tion with the hnRNP SAF-B/HET.79 SAF-B/HET is thought to 
serve as a molecular platform to assemble a transcription complex 
in the vicinity of actively transcribed genes,95 a mechanism which 
appears to be highly conserved among several species.96
However, only few studies demonstrate a direct or indirect 
impact on gene transcription following the perturbation of ZO-2 
levels. For instance, in vascular smooth muscle cells (VSMCS) 
of coronary arteries the expression of STAT1 (signal transduc-
ers and activators of transcription)-specific genes is upregulated 
in response to ZO-2 silencing.97 Another study demonstrates 
the association of ZO-2 with the non-receptor tyrosine kinase 
JAK1 (Janus kinase 1) in VMSCs mediating specific homotypic 
in cytoskeletal regulation.67 ZO-2, next to ZO-1,58 also associ-
ates with the basolateral polarity protein Scribble (huScribble) 
via a C-terminal motif57 and the ZO-2/Scribble complex appears 
to be involved in TJ assembly and function.58 Finally, protein 
kinases, signaling molecules and other regulatory proteins includ-
ing cytokines which directly or indirectly target ZO-2 complete 
the dynamic network of the ZO-2 scaffold. These include vari-
ous isoforms of protein kinase C,68-70 the tyrosine kinase c-Src 
and its negative regulator Csk (C-terminal Src kinase)71 as well 
as the heterotrimeric G protein Galpha12,72 which promotes Src 
phosphorylation of ZO-1 and ZO-2 resulting in disruption of TJs 
and an increase in paracellular permeability.73 Interestingly, next 
to ZO-2 itself, several of the interacting proteins resemble “dual-
residency” proteins, capable of shuttling between the cytoplasm 
and the nucleus. Therefore, ZO-2 serves as a molecular hub at the 
cytoplasmic aspect of TJs. In addition, the nuclear translocation 
of ZO-2 together with bound proteins substantially extends the 
physiological functions of this junctional MAGUK protein.
Nuclear ZO-2 and the Impact of ZO-2  
on Transcription and Cell Proliferation
The presence of ZO-2 within the nucleus has been recognized 
more than a decade ago. All ZO proteins carry conserved nuclear 
localization and nuclear export sequences,74 however only ZO-1 
and ZO-2 have been shown to localize to cell nuclei of epithe-
lial and endothelial cells.75-79 In sparse cultures, ZO-1 and ZO-2 
are present in cell nuclei but become redistributed to the plasma 
membrane as soon as cells reach confluence.76,77 During mitosis 
and the concomitant disintegration of the nuclear membrane 
ZO-2 is evenly dispersed within the cytoplasm and during the 
late G1 phase ZO-2 accumulates in the nucleus. In quiescent cells 
ZO-2 is not present in the nucleus.80 Further, it was demonstrated 
that ZO-2 preferentially targets the nuclei of epithelial cells dur-
ing and upon chemical and heat stress.79 Frequently, nuclear ZO-2 
locates to nuclear speckles, which is dependent on the presence 
of an intact PDZ-1 domain78 and potentially can be induced by 
the interaction with the heterogeneous nuclear ribonucleopro-
tein SAF-B/HET (scaffold attachment factor-B/HSP27 estro-
gen response element-TATA box-binding protein).79 In addition, 
recruitment of ZO-2 to nuclear speckles requires binding to phos-
phatidylinositol 4,5-bisphosphate,81 a phospholipid component of 
plasma membranes.
The notion that junctional MAGUKs fulfill functions next to 
their prime role in aiding in the establishment of cell-cell junc-
tions is not without precedence. A first clue came from studies 
with the Drosophila tumor suppressor protein Dlg, a protein rel-
evant for the formation of invertebrate septate junctions and neu-
ronal synaptic junctions. Genetic studies in Drospohila revealed 
that mutations in Dlg resulted in tumorous overgrowth of imagi-
nal discs.82,83 Due to their high homology with Dlg it was specu-
lated that the ZO family of MAGUK proteins, including ZO-2, 
are also involved in cell growth and proliferation. Indeed, several 
studies have demonstrated the interaction of ZO proteins with 
proteins involved in cell cycle progression and transcriptional 
regulation.24,26,36 However, results from studies investigating the 
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that ZO-2 is involved in cytoprotection by modulating Hsp27 
expression levels (Fig. 3). Further, in vitro studies have shown 
that cerebral endothelial cells, stably overexpressing nuclear 
ZO-2, show a moderate decrease in MMP9 (matrix metallopro-
teinase 9) mRNA levels.106 The underlying mechanism explaining 
the modulation of MMP9 levels by ZO-2 remains to be deter-
mined. Nevertheless, it has been demonstrated several-fold that 
the downregulation of MMP9 exerts a protective effect on the 
endothelial barrier, particularly the blood-brain barrier, follow-
ing ischemic damage.107-111 Further, in human breast carcinoma 
cells MMP9 was shown to be suppressed by heme oxygenase 1 
(HO-1), a target gene of the transcriptional repressor Bach1.112,113 
Interestingly, via a yeast based Two-hybrid assay, we identified 
Bach1 to interact directly with ZO-2 (unpublished data). It will 
be of particular interest to determine whether and how this inter-
action modulates HO-1 levels and potentially contributes to the 
cytoprotective action of HO-1.
As mentioned before, ZO-2 has also been shown to directly 
or indirectly act as a negative regulator of STAT-1 expression in 
VSMCs.95 Interestingly, the JAK/STAT pathway mediates HIV-
induced adhesion and transmigration of monocytes across the 
blood-brain barrier in vitro through increased expression of IL-6 
and IL-8.114 It will be interesting to determine whether or not 
ZO-2 suppresses STAT-1 expression in cerebral endothelial cells 
as well, thereby exerting a protective effect in HIV-induced neuro-
inflammation by decreasing the JAK/STAT-mediated leukocyte 
entry into the brain.
Many TJ proteins have been shown to be directly targeted 
by viruses with oncogenic and non-oncogenic potential, often 
resulting in a perturbation of the junctional barrier of their tar-
get cells.115,116 As a result, the dissemination and transmission 
efficiency of the viruses is often increased.
Oxidative stress also alters ZO protein expression and local-
ization in a number of pathologies, including hypoxia, bacterial 
and viral infections, inflammation and age-related diseases.117 
However, most of the studies have focused on ZO-1 and on 
increased permeability of epithelial and endothelial barriers 
and information concerning redundant and non-redundant 
intercellular contacts.98 Together, these 
observations suggest that ZO-2 is poten-
tially involved in vascular remodel-
ing and arteriogenesis. Overexpression 
of ZO-2 was also shown to increase 
β-catenin phosphorylation, thereby 
reducing β-catenin-mediated gene 
transcription of Wnt target genes.99 In 
nasal epithelial cells, the experimentally 
induced upregulation of ZO-2 expres-
sion through activation of PKC signal-
ing was shown to be inhibited by the 
transcriptional factor GATA-3.70 Finally, 
in a human genome-wide siRNA screen 
ZO-2 has been identified as a novel 
NFκB activation pathway component.100 
However, for many of these observations 
the physiological ramifications remain 
poorly defined.
Taken together, one can postulate that not only peripheral, 
but also nuclear ZO-2 serves as a scaffold protein facilitating the 
transport of other proteins to the nucleus, aiding in the spatial and 
temporal assembly of nuclear “transcriptomes,” thereby directly or 
indirectly influencing cell proliferation and/or gene transcription.
The Role of ZO-2 in Stress Response  
and Health and Disease
ZO-2 has also been associated with several human pathologies. 
Clinical studies revealed that, e.g., familial hypercholanemia 
or nonsyndromic progressive hearing loss are associated with 
mutations of the ZO-2 gene and/or a change in ZO-2 protein 
levels.101,102 Due to the high degree of homology between the 
Drosophila tumor suppressor protein Dlg and ZO-1, together 
with the actions of ZO-2 on cell proliferation and gene tran-
scription, it is also tempting to speculate that ZO-2 could act as 
a tumor suppressor. Indeed, in several tumors the mRNA levels 
of ZO-2 are reduced (reviewed in 103). However, most of these 
reports do not exclude that the reduction of ZO-2 and/or other 
junctional proteins is a consequence of the disease.
Recently, Bautista-Garcia et al. demonstrated a cytoprotec-
tive function of ZO-2. In a mouse model of adricmycin-induced 
kidney dysfunction overexpression of ZO-2 prevents podocyte 
injury by increasing phosphorylated β-catenin and decreasing the 
expression of Wnt/β-catenin downstream genes.99 The interfer-
ence of ZO-2 with the Wnt/β-catenin signaling pathway predicts 
an unforeseeable array of functions in biological processes where a 
fine-tuned balance between differentiation, cell growth and cell-
cell adhesion is required. This includes the modulation of all types 
of epithelial-mesenchymal transition (EMT) underlying develop-
ment, tissue regeneration and disease.104
ZO-2 is also potentially involved in cellular stress responses. 
For instance, upon chemical stress and heat shock, ZO-2 accumu-
lates in the nucleus of epithelial cells.79 Since nuclear ZO-2 associ-
ates directly with SAF-B/HET, a negative regulator of the heat 
shock protein 27 (Hsp27) transcription,105 one could extrapolate 
Figure 3. Functions of Zo-2 beyond cell-cell adhesion. The expression and intracellular distribution 
of the junctional MAgUK protein Zo-2 is influenced by various extrinsic and intrinsic cues, including 
cellular stress and cell-cell contact. in response Zo-2 affects diverse cellular processes, including cell 
proliferation, apoptosis, stress tolerance and barrier integrity by directly or indirectly influencing 
gene expression, ultimately feeding into various cell signaling pathways.
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proliferation. ZO-1/2 protein expression and localization also has 
been shown to be altered during cellular stress responses (i.e., oxi-
dative stress or hypoxia117) and various other pathologies. More 
recently, ZO-2 has further been shown to exert a cytoprotective 
effect by perturbing the Wnt/β-catenin pathway, preventing podo-
cyte injury in a mouse model. Much remains to be learned and 
additional studies dissecting the molecular mechanism(s) underly-
ing the proposed ZO-2-mediated cytoprotective response pathways 
are required, providing ample opportunities for future research.
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functions of ZO proteins upon oxidative stress is still missing. 
Of particular interest in this context is the role of nuclear ZO-2 
for the cellular stress response.
In summary, TJ-associated proteins in general and ZO-2 in 
particular have been associated with a multitude of physiological 
and pathological conditions other than forming and maintaining 
the tight junction permeability barrier.
Summary
Historically, the multi PDZ domain MAGUK protein ZO-2 was 
believed to serve as a simple structural component of the “cyto-
plasmic plaque” of TJs. However, the recognition that ZO-2 tran-
siently targets the nucleus of epithelial and endothelial cells has 
fuelled intense interest over the years and has led to the discovery 
of a myriad of functions extending beyond the assembly of TJs, 
including the modulation of gene transcription, cell growth and 
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